Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy

被引：0

作者：

Gold, Linda Stein ^{[1
]}

Kircik, Leon ^{[2
,3
,4
]}

Sugarman, Jeffrey ^{[5
]}

Lin, Tina ^{[6
]}

Pillai, Radhakrishnan ^{[7
]}

Varughese, Johnson ^{[7
]}

机构：

[1] Henry Ford Hosp, Detroit, MI 48202 USA

[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[3] Phys Skin Care PLLC, Louisville, KY USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Ortho Dermatol, Bridgewater, NJ USA

[7] Bausch Hlth, Bridgewater, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

9859

引用

页码：AB69 / AB69

页数：1

共 50 条

[1] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Gold, Linda Stein
Lain, Edward
Green, Lawrence J.
Lin, Tina
Israel, Robert
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 815 - 820
[2] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Pariser, David M.
Green, Lawrence J.
Gold, Linda Stein
Sugarman, Jeffrey L.
Lin, Tina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 723 - 726
[3] Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
Lebwohl, Mark G.
Gold, Linda Stein
Del Rosso, James Q.
Green, Lawrence
Jacobson, Abby
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2068 - 2074
[4] Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion
Gold, L. F. Stein
Lebwohl, M. G.
Bhatia, N.
Lin, T.
Pillai, R.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
[5] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
Kircik, Leon H.
Papp, Kim A.
Gold, Linda Stein
Harris, Susan
Lin, Tina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
[6] Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Blauvelt, Andrew
Green, Lawrence J.
Lebwohl, Mark G.
Yamauchi, Paul S.
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 297 - 299
[7] Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females
Gold, Linda Stein
Elewski, Boni
Draelos, Zoe
Jacobson, Abby
Lin, Tina
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (05) : 504 - 514
[8] Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities
Bhatia, Neal D.
Vlahovic, Tracey C.
Green, Lawrence G.
Martin, Gina
Lin, Tina
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (10) : 1029 - 1036
[9] Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination
Gold, Linda Stein
Kircik, Leon H.
Pariser, David
Sugarman, Jeffrey L.
Lin, Tina
Kang, Robert
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 863 - 868
[10] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
Brownstone, Nicholas D.
Bhutani, Tina
Koo, John
CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25

← 1 2 3 4 5 →